今日盘中，生物制药公司吉利德科学（Gilead Sciences）股价大涨5.23%，引起市场广泛关注。据悉，这一涨幅主要受到分析师对公司核心产品销售预期的提振。
加拿大皇家银行资本市场（RBC Capital Markets）发布报告称，预计吉利德公司的艾滋病预防药物Yeztugo在第三季度的销售额将超过市场一致预期。分析师预计Yeztugo销售额可达4500万美元，远高于市场预期的3500万美元，主要得益于转换需求和早期市场吸收。此外，RBC还预计吉利德的另一款重磅艾滋病药物Biktarvy的第三季度销售额也将超出预期。
值得注意的是，吉利德科学将于本月底公布第三季度财报，投资者对此充满期待。尽管CVS暂时决定不覆盖Yeztugo，以及处方集延迟和继续使用仿制药Truvada可能会限制该药的近期使用量，但市场对吉利德的长期增长前景仍保持乐观。截至目前，该公司股价今年累计上涨33.98%，显示出强劲的市场表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.